Association between elevated C-reactive protein and mortality, healthcare resource utilization and costs in patients with atherosclerotic cardiovascular disease and/or chronic kidney disease

Clicks: 13
ID: 332346
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #57 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) impact health and healthcare systems. Inflammation is a potential modifiable risk factor for both conditions. The case for evaluating the modification of inflammation in these conditions could be strengthened by evidence that systemic inflammation (C-reactive protein [CRP] ≥2 mg/L) was associated with a considerable health burden. Methods A retrospective observational cohort study of 179 261 individuals in mutually exclusive cohorts (ASCVD only, CKD stages 3–4 only, ASCVD+CKD stages 3–4) and a reference cohort (no ASCVD or CKD) with ≥1 CRP measurement after diagnosis. Outcomes included all-cause mortality, healthcare resource utilization (HCRU) and direct healthcare costs. Results CKD stages 3–4, ASCVD only and ASCVD+CKD stages 3–4 cohorts compared with the reference cohort were associated with increasing all-cause mortality (death/100 000 person-years) of 1637, 2090, 5163 and 946, respectively. HCRU events per person per year (PPPY) and mean direct costs PPPY were 20.4, 21.4, 34.2 and 8.2 and £2593, £3098, £6810 and £1144, respectively. Within cohorts, all-cause mortality increased progressively across CRP quartiles (Q) and was highest in Q4 among the ASCVD+CKD stages 3–4 cohort, with a hazard ratio (Q4 vs Q1) of 2.75 in this cohort compared with 1.22 in the reference cohort. Conclusions While the clinical impact of targeting inflammation is being evaluated in ongoing trials, this real-world study demonstrates that assessing inflammation in patients with ASCVD and CKD stages 3–4 can help to identify a population with a high healthcare burden.
Reference Key
openalex_W7221787746 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kausik Kumar Ray, Fotios Barkas, Eline L. Huisman, Jimmi Mathisen, Iram Faqir Muhammad, Hongye Ren, Simon Bertram Reuter, Jonathan Pearson‐Stuttard, Andrew Thompson
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag177
URL
https://doi.org/10.1093/ehjopen/oeag177
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.